Unbalanced expression of HLA-A and -B antigens: a specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-gamma

Int J Cancer. 2001 Feb 15;91(4):500-7. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1076>3.0.co;2-i.

Abstract

Conflicting evidences suggested that levels of HLA-A and -B antigens expressed on normal and neoplastic cells of given individuals are genetically predetermined, or, on the other hand, regulated by molecular mechanisms generating the down-regulated expression of HLA-B antigens frequently observed on melanoma cells. In our study, we quantitated, both at the protein and mRNA level, the amounts of HLA-A and -B antigens constitutively expressed on 23 primary cultures of metastatic melanomas and on autologous peripheral blood mononuclear cells (PBMC). Flow cytometric analyses identified a significantly (p < 0.01) lower expression of HLA-B antigens on melanoma cell cultures but not on autologous PBMC. Consistently, lower amounts of HLA-B antigens mRNA were detected by RNase protection assay exclusively in neoplastic cells. This unbalanced expression of HLA-A and -B antigens was readily reverted by interferon (IFN)-gamma but not by the DNA hypomethylating agent 5-aza-2'-deoxycytidine in 4 melanoma cell cultures investigated. Significantly (p < 0.05) lower levels of HLA-B antigens were also detected on cells from solid malignancies of different histotypes but not on neoplastic cells from hemopoietic neoplasms; levels of HLA-B antigens were rapidly up-regulated by IFN-gamma exclusively on non-hemopoietic transformed cells. Together, these data strongly argue against a genetic predetermination of the amounts of HLA-A and -B antigens expressed on normal and neoplastic cells of distinct melanoma patients and suggest that constitutively low levels of HLA-B antigens are a specific feature of non-hemopoietic transformed cells that is controlled by common regulatory mechanism(s) and that is possibly shared by non-hemopoietic normal cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Azacitidine / analogs & derivatives*
  • Azacitidine / therapeutic use
  • Base Sequence
  • Cells, Cultured
  • DNA, Complementary / metabolism
  • Decitabine
  • Down-Regulation
  • Flow Cytometry
  • HLA-A Antigens / biosynthesis*
  • HLA-A Antigens / genetics
  • HLA-B Antigens / biosynthesis*
  • HLA-B Antigens / genetics
  • Humans
  • Interferon-gamma / therapeutic use*
  • Leukocytes, Mononuclear / metabolism
  • Melanoma / genetics
  • Melanoma / metabolism*
  • Molecular Sequence Data
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Phenotype
  • RNA, Messenger / metabolism
  • Recombinant Proteins / metabolism
  • Ribonucleases / metabolism
  • Sequence Homology, Nucleic Acid
  • Skin Neoplasms / genetics
  • Skin Neoplasms / metabolism
  • Tumor Cells, Cultured
  • Up-Regulation

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • DNA, Complementary
  • HLA-A Antigens
  • HLA-B Antigens
  • RNA, Messenger
  • Recombinant Proteins
  • Decitabine
  • Interferon-gamma
  • Ribonucleases
  • Azacitidine